Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Leukemia, Prolymphocytic, T-Cell × Clear all
NCT04771572 2026-05-05

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Newave Pharmaceutical Inc

Phase 1 Recruiting
100 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis